European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting NewsPerspective

Post-hoc analysis supports pembrolizumab’s benefit in recurrent head, neck squamous cell carcinoma

October 22, 2018
MUNICH — A post-hoc analysis of the randomized phase 3 KEYNOTE-040 trial presented at European Society for Medical Oncology Congress showed a…
Meeting News

SD-101 plus pembrolizumab induces response in recurrent, metastatic head and neck cancer

October 22, 2018
MUNICH — The addition of SD-101 to pembrolizumab induced a promising response rate among patients with recurrent or metastatic head and neck…
Meeting News

Vandetanib shows promise for advanced thyroid cancer

October 22, 2018
MUNICH — Vandetanib induced tumor shrinkage that persisted throughout multiple treatment lines for patients with advanced unresectable…
Meeting News

Lenvatinib plus pembrolizumab effective for thyroid cancer subset

October 22, 2018
MUNICH — The combination of lenvatinib and pembrolizumab appeared effective for a small cohort of patients with metastatic anaplastic or poorly…
Meeting NewsPerspective

Olaparib confers ‘unprecedented’ PFS benefit in ovarian cancer

October 21, 2018
MUNICH — Maintenance olaparib significantly improved PFS among women with advanced ovarian cancer who harbored BRCA1 or BRCA2 mutations…
Meeting NewsPerspective

Local radiotherapy extends survival for certain men with metastatic prostate cancer

October 21, 2018
MUNICH — Radiotherapy to the prostate did not prolong survival for unselected men with newly diagnosed metastatic prostate cancer, according to…
Meeting NewsPerspective

Avelumab-axitinib combination may be new first-line standard for advanced renal cell carcinoma

October 21, 2018
MUNICH — The combination of avelumab and axitinib significantly improved PFS compared with standard sunitinib among previously untreated…
Meeting NewsPerspective

Experimental regimen prolongs PFS in recurrent ovarian cancer

October 21, 2018
MUNICH — Women with recurrent ovarian cancer treated with carboplatin, pegylated liposomal doxorubicin and bevacizumab achieved longer PFS than…
Meeting NewsPerspective

Multistrain probiotic may reduce mild, moderate chemotherapy-induced diarrhea

October 21, 2018
MUNICH — A high-potency multistrain probiotic may help reduce mild or moderate chemotherapy-induced diarrhea among individuals with cancer…
Meeting News

Shorter trastuzumab course may be viable for some women with early HER2-positive breast cancer

October 21, 2018
MUNICH — A 9-week course of adjuvant trastuzumab offered the same DFS benefit but with less cardiac toxicity than a 1-year course for women…